Billion-dollar M&As are commonplace now, but not too long ago they were a rarity. So many have occurred in the past few years, they've become the norm. But were all these multi-billion-dollar mega mergers worth the money? Karen Carey, BioWorld's senior managing editor and chief analyst, crunched the numbers on 21 of the biggest M&As in a three-part BioWorld series and found very few have been, so far, good deals for the buyer. In this podcast, Carey sifts through the winners and losers and explains the analysis.
Podden och tillhörande omslagsbild på den här sidan tillhör
BioWorld. Innehållet i podden är skapat av BioWorld och inte av,
eller tillsammans med, Poddtoppen.
